Analysts Set Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Price Target at $173.07

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has earned a consensus rating of “Moderate Buy” from the fourteen research firms that are currently covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and eleven have assigned a buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $173.07.

A number of equities research analysts have weighed in on JAZZ shares. Wells Fargo & Company decreased their price objective on Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating on the stock in a report on Thursday, August 1st. The Goldman Sachs Group started coverage on shares of Jazz Pharmaceuticals in a research note on Wednesday, June 5th. They set a “buy” rating and a $169.00 price target for the company. HC Wainwright reiterated a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, August 1st. JPMorgan Chase & Co. boosted their target price on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an “overweight” rating in a research note on Monday, August 19th. Finally, Morgan Stanley lowered their price objective on shares of Jazz Pharmaceuticals from $160.00 to $150.00 and set an “equal weight” rating for the company in a research report on Friday, July 12th.

Jazz Pharmaceuticals Price Performance

NASDAQ JAZZ opened at $109.04 on Wednesday. The business’s fifty day moving average is $111.06 and its two-hundred day moving average is $110.69. The stock has a market capitalization of $6.88 billion, a P/E ratio of 22.48, a P/E/G ratio of 1.36 and a beta of 0.57. The company has a debt-to-equity ratio of 1.36, a quick ratio of 2.02 and a current ratio of 2.37. Jazz Pharmaceuticals has a 1 year low of $99.06 and a 1 year high of $137.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.80 by $0.87. The company had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1 billion. Jazz Pharmaceuticals had a return on equity of 28.65% and a net margin of 10.10%. On average, research analysts forecast that Jazz Pharmaceuticals will post 16.03 earnings per share for the current fiscal year.

Insider Activity

In related news, SVP Mary Elizabeth Henderson sold 1,410 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $108.30, for a total value of $152,703.00. Following the completion of the sale, the senior vice president now owns 14,531 shares in the company, valued at approximately $1,573,707.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 4.20% of the company’s stock.

Institutional Trading of Jazz Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. Capital World Investors bought a new position in shares of Jazz Pharmaceuticals during the first quarter valued at $171,943,000. Swedbank AB purchased a new stake in Jazz Pharmaceuticals in the 2nd quarter worth $106,936,000. Vestal Point Capital LP bought a new stake in Jazz Pharmaceuticals during the fourth quarter valued at about $89,175,000. Rubric Capital Management LP purchased a new position in shares of Jazz Pharmaceuticals in the second quarter valued at about $65,812,000. Finally, Pacer Advisors Inc. grew its position in shares of Jazz Pharmaceuticals by 40.7% during the second quarter. Pacer Advisors Inc. now owns 1,820,913 shares of the specialty pharmaceutical company’s stock worth $194,346,000 after purchasing an additional 527,187 shares in the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.